Publications by authors named "Jantien Wanders"

Claim this Profile
E
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.
Hyman Muss, Javier Cortes, Linda T Vahdat, Fatima Cardoso, Chris Twelves, Jantien Wanders

Oncologist· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.
Thierry Lesimple, Julien Edeline, Timothy J Carrothers, Frédérique Cvitkovic, Borje Darpo, Jantien Wanders

Invest New Drugs· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
Lot A Devriese, Petronella Els O Witteveen, Jantien Wanders, Kenneth Law, Geoff Edwards

Br J Clin Pharmacol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.
Elena Soto, Ron J Keizer, Iñaki F Trocóniz, Alwin D R Huitema, Jos H Beijnen, Jantien Wanders

Invest New Drugs· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
Patrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi, Nguyen Bin Bui, Sebastian Bauer, Jantien Wanders

Lancet Oncol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report.
David S Boss, Hilary Glen, Jos H Beijnen, Daphne de Jong, Jantien Wanders

Tumori· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Javier Cortes, Joyce O'Shaughnessy, David Loesch, Joanne L Blum, Linda T Vahdat, Jantien Wanders

Lancet· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Javier Cortes, Linda Vahdat, Joanne L Blum, Chris Twelves, Mario Campone, Jantien Wanders

J Clin Oncol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.
Ron J Keizer, Anubha Gupta, Melvin R Mac Gillavry, Mendel Jansen, Jantien Wanders

J Pharmacokinet Pharmacodyn· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
Chris Twelves, Javier Cortes, Linda T Vahdat, Jantien Wanders, Corina Akerele

Clin Breast Cancer· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820.
Ron J Keizer, Miren K Zamacona, Mendel Jansen, David Critchley, Jantien Wanders

Invest New Drugs· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.
Anthe S Zandvliet, Jan H M Schellens, Christian Dittrich, Jantien Wanders, Jos H Beijnen

Br J Clin Pharmacol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors.
Moritz N Wente, Jörg Kleeff, Markus W Büchler, Jantien Wanders, Peter Cheverton

Invest New Drugs· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
Charlotte van Kesteren, Anthe S Zandvliet, Mats O Karlsson, Ron A A Mathôt, Cornelis J A Punt, Jantien Wanders

Invest New Drugs· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
Maja J A de Jonge, Ate van der Gaast, André S T Planting, Leny van Doorn, Aletta Lems, Jantien Wanders

Clin Cancer Res· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.
Alain Ravaud, Thomas Cerny, Catherine Terret, Jantien Wanders, Binh Nguyen Bui

Eur J Cancer· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.
Francesco Caponigro, Pax Willemse, Roberto Sorio, Anne Floquet, Simon van Belle, Jantien Wanders

Invest New Drugs· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
Otto Soepenberg, Maja J A de Jonge, Alex Sparreboom, Peter de Bruin, Ferry A L M Eskens, Jantien Wanders

Clin Cancer Res· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Christian Dittrich, Herlinde Dumez, Hilary Calvert, Axel Hanauske, Marije Faber, Jantien Wanders

Clin Cancer Res· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.
Emmanuelle Comets, Kazumasa Ikeda, Paulo Hoff, Pierre Fumoleau, Jantien Wanders

J Pharmacokinet Pharmacodyn· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
Andreas M Kaufmann, Peter L Stern, Elaine M Rankin, Harald Sommer, Volkmar Nuessler, Jantien Wanders

Clin Cancer Res· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis